Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24191454 | 0.90 | AKT1 (0.59) | AKT1HDAC1HDAC6ACEHDAC3 | |
| SCHEMBL17003656 | 0.86 | FAAH (0.50) | AKT1HDAC1HDAC6HDAC3HDAC4 | |
| SCHEMBL20787950 | 0.86 | FAAH (0.50) | AKT1HDAC1HDAC6HDAC3HDAC4 | |
| SCHEMBL29114311 | 0.85 | FAAH (0.51) | AKT1HDAC1HDAC6HDAC3HDAC4 | |
| SCHEMBL29235949 | 0.85 | FAAH (0.51) | AKT1HDAC1HDAC6HDAC3HDAC4 | |
| SCHEMBL25749157 | 0.85 | AKT1 (0.52) | AKT1HDAC1HDAC6HDAC3HDAC4 | |
| SCHEMBL24344052 | 0.85 | AKT1 (0.52) | AKT1HDAC1HDAC6HDAC3HDAC4 | |
| SCHEMBL24343455 | 0.85 | AKT1 (0.52) | AKT1HDAC1HDAC6HDAC3HDAC4 | |
| SCHEMBL25975485 | 0.84 | AKT1 (0.50) | AKT1HDAC1HDAC6HDAC3HDAC4 | |
| SCHEMBL25967838 | 0.84 | AKT1 (0.50) | AKT1HDAC1HDAC6HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250049782-A1 | ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-02-13 | — | — | US | disclosed |
| US-12186310-B2 | Antibody-drug conjugate | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-01-07 | — | — | US | disclosed |
| EP-4464707-A2 | ANTI-HER2 ANTIBODY-DRUG CONJUGATE | Daiichi Sankyo Company, Limited (JP) | 2024-11-20 | — | — | EP | disclosed |
| EP-4212552-B1 | ANTI-HER2 ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO CO LTD (JP) | 2024-11-13 | — | — | EP | disclosed |
| US-20240082413-A1 | ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-03-14 | — | — | US | disclosed |
| US-20240026030-A1 | METHOD OF TREATING CANCER COMPRISING ADMINISTRATION OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-01-25 | — | — | US | disclosed |
| US-11795236-B2 | Method for treating cancer comprising administration of anti-HER2 antibody-drug conjugate | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-10-24 | — | — | US | disclosed |
| EP-4212552-A1 | ANTI-HER2 ANTIBODY-DRUG CONJUGATE | Daiichi Sankyo Company, Limited (JP) | 2023-07-19 | — | — | EP | disclosed |
| US-11633493-B2 | Antibody-drug conjugate | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-04-25 | — | — | US | disclosed |
| US-11633493-B2 | Antibody-drug conjugate | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-04-25 | — | — | US | disclosed |
| CN-113929738-A | Antibody-drug conjugates | 第一三共株式会社 | 2022-01-14 | — | — | CN | disclosed |
| US-10973924-B2 | Antibody-drug conjugate | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-04-13 | — | — | US | disclosed |
| US-20200385486-A1 | METHOD OF TREATING CANCER COMPRISING ADMINISTRATION OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-12-10 | — | — | US | disclosed |
| US-20200282073-A1 | ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-09-10 | — | — | US | disclosed |
| US-20190077880-A1 | ANTI-HER2 ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-03-14 | — | — | US | disclosed |
| US-10195288-B2 | Antibody-drug conjugate | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-02-05 | — | — | US | disclosed |
| US-9808537-B2 | Antibody-drug conjugate | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-11-07 | — | — | US | disclosed |
| US-20160333112-A1 | ANTI-HER2 ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-11-17 | — | — | US | disclosed |
| US-20160279259-A1 | ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-09-29 | — | — | US | disclosed |
| US-20150297748-A1 | ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11633493-B2 | Antibody-drug conjugate | LANCL2, LANCL1, LCLAT1 | AKT1 3425/4885MAOA 1501/4885HDAC1 1373/4885 |
| US-20240026030-A1 | METHOD OF TREATING CANCER COMPRISING ADMINISTRATION OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE | ERBB2, EGFR, H1-2 | AKT1 3358/4885MAOA 1062/4885HDAC1 1363/4885 |
| US-20200385486-A1 | METHOD OF TREATING CANCER COMPRISING ADMINISTRATION OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE | ERBB2, EGFR, H1-2 | AKT1 3287/4885MAOA 1198/4885HDAC1 1333/4885 |
| US-20200282073-A1 | ANTIBODY-DRUG CONJUGATE | LANCL2, LANCL1, LCLAT1 | AKT1 3425/4885MAOA 1501/4885HDAC1 1373/4885 |
| US-20160333112-A1 | ANTI-HER2 ANTIBODY-DRUG CONJUGATE | ERBB2, EGFR, H1-2 | AKT1 2462/4885MAOA 1485/4885HDAC1 1596/4885 |
| US-10973924-B2 | Antibody-drug conjugate | LANCL2, LANCL1, LCLAT1 | AKT1 3306/4885MAOA 1651/4885HDAC1 1273/4885 |
| US-10195288-B2 | Antibody-drug conjugate | LANCL2, LANCL1, LCLAT1 | AKT1 3306/4885MAOA 1651/4885HDAC1 1273/4885 |
| US-20160279259-A1 | ANTIBODY-DRUG CONJUGATE | LANCL2, LANCL1, LCLAT1 | AKT1 3306/4885MAOA 1651/4885HDAC1 1273/4885 |
| US-11795236-B2 | Method for treating cancer comprising administration of anti-HER2 antibody-drug conjugate | ERBB2, EGFR, ERBB3 | AKT1 3339/4885MAOA 1199/4885HDAC1 1301/4885 |
| US-12186310-B2 | Antibody-drug conjugate | LANCL2, LANCL1, LCLAT1 | AKT1 3306/4885MAOA 1651/4885HDAC1 1273/4885 |
| US-20240082413-A1 | ANTIBODY-DRUG CONJUGATE | LANCL2, LANCL1, LCLAT1 | AKT1 3306/4885MAOA 1651/4885HDAC1 1273/4885 |
| US-20190077880-A1 | ANTI-HER2 ANTIBODY-DRUG CONJUGATE | ERBB2, EGFR, H1-2 | AKT1 2371/4885MAOA 1485/4885HDAC1 1625/4885 |
| US-20250049782-A1 | ANTIBODY-DRUG CONJUGATE | LANCL2, LCLAT1, LANCL1 | AKT1 3051/4885MAOA 1556/4885HDAC1 1407/4885 |
| US-20150297748-A1 | ANTIBODY-DRUG CONJUGATE | LANCL2, LANCL1, LCLAT1 | AKT1 3306/4885MAOA 1651/4885HDAC1 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.